EpiCypher, Inc. Launches New Website and New Identity

Research Triangle Park, N.C. –February 17, 2015 – EpiCypher today announced the launch of a new version of EpiCypher.com . Key benefits of the new site include a cleaner & more attractive design, a more engaging user experience with enhanced search, improved navigation and deeper e-commerce capabilities. The new online presence provides fast and intuitive access to the company’s deep product lines as well as extensive resources for scientists with demanding needs in epigenetic and chromatin biology.

The website was created with the user experience firmly in mind. For mobile applications in particular, the site delivers an excellent user experience using the latest technology. The site’s refreshed & simplified look, enhanced content, improved search functionality, and optimization for mobile devices allows visitors to immerse themselves in the depth of EpiCyphers capability.

Our mission is to connect scientist and researchers to the latest in epigenetic tools, products and services. “The science-centric design of the site provides an innovative platform for researchers that will boost the applicability of our products and services to researchers needs, and thus further their discoveries,” says EpiCypher CEO, Sam C. Tetlow.

About EpiCypher

Pioneering the Science of Epigenetics™

A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide.

EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com .

Contacts:

Sam Tetlow, CEO

EpiCypher, Inc.

919-627-7882 (direct)

sam@epicypher.com

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC